Supproting Materials for "Cross-Linked Selenoctanoic Acid Nanoplatform Enables Bidirectional Regulation of Intra- and Extracellular ROS: A New Avenue for Enhanced Cancer Immunotherapy" - section B
<h1><strong>Table of Content</strong></h1> <h1>1. Synthesis and characterization</h1> <h2> 1.1. SeLA</h2> <h3> 1.1.0. Lab book pages</h3> <h3> 1.1.1. NMR</h3> <h3> 1.1.2. HR-MS</h3> <h3> 1.1.3. UV</h3> <h3> 1.1.4. IR</h3> <h2> 1.2. cSeLAN</h2> <h3> 1.2.0. Lab book pages</h3> <h3> 1.2.1. NMR</h3> <h3> 1.2.2. UV</h3> <h3> 1.2.3. IR</h3> <h3> 1.2.4. GPC</h3> <h3> 1.2.5. MALDI-TOF-MS</h3> <h3> 1.2.6. DLS</h3> <h3> 1.2.7. Critical melle cncentration</h3> <h3> 1.2.8. ICP-MS</h3> <h3> 1.2.9. TEM</h3> <h2> 1.3. cLAN</h2> <h3> 1.3.0. Lab book pages</h3> <h3> 1.3.1. NMR</h3> <h3> 1.3.2. UV</h3> <h3> 1.3.3. DLS</h3> <h3> 1.3.4. GPC</h3> <h1>2. <em>In vitro</em> intra- and extracellular ROS regulation</h1> <h2> 2.0. Lab book pages</h2> <h2> 2.1. Raman scattering spectra</h2> <h2> 2.2. HPLC</h2> <h3> 2.2.1. Standard peaking</h3> <h3> 2.2.2. HPLC analysis</h3> <h2> 2.3. ICP-MS</h2> <h2> 2.4. MTT</h2> <h2> 2.5. Intracellular ROS generation</h2> <h3> 2.5.1. Fluorescence images</h3> <h3> 2.5.2. Flow fluorescence quantification</h3> <h2> 2.6. Intracellular pro-oxidation mechanism</h2> <h3> 2.6.1. Quantification of intracellular ATP</h3> <h3> 2.6.2. Quantification of intracellular NADH</h3> <h3> 2.6.3. Quantification of intracellular <strong>·</strong>OH</h3> <h3> 2.6.4. Quantification of intracellular ROS</h3> <h2> 2.7. Quantification of extracellular ROS</h2> <h1>3. <em>In vitro</em> ICD-inducing ability</h1> <h2> 3.0. Lab book pages</h2> <h2> 3.1. ATP release</h2> <h2> 3.2. HMGB1</h2> <h2> 3.3. CRT</h2> <h1>4. T cell proliferation and activation</h1> <h2> 4.0. Lab book pages</h2> <h2> 4.1. Flow cytometry analysis of the T cell proliferation</h2> <h2> 4.2. Quantification of IFN-γ secretions</h2> <h1>5. Biosafety evaluation of cSeLAN</h1> <h2> 5.0. Lab book pages</h2> <h2> 5.1. Hemolytic and hemagglutination assay</h2> <h3> 5.1.1. Hemolytic assay</h3> <h3> 5.1.2. Hemagglutination assay</h3> <h2> 5.2. Acute toxicity test</h2> <h3> 5.2.1. The amounts of dead mice</h3> <h3> 5.2.2. Body weight of mice</h3> <h3> 5.2.3. Hematological assay</h3> <h3> 5.2.4. Blood biochemistry</h3> <h3> 5.2.5. H&E staining of main organs</h3> <h1>6. Pharmacokinetic evaluation of cSeLAN</h1> <h2> 6.0. Lab book pages</h2> <h2> 6.1 Pharmacokinetic evaluation of cSeLAN</h2> <h1>7. <em>In vivo</em> anti-tumor immune response</h1> <h2> 7.0. Lab book pages</h2> <h2> 7.1. Chemiluminescence images</h2> <h3> 7.1.1. Chemiluminescence images of isoluminol</h3> <h3> 7.1.2. Chemiluminescence images of luminol</h3> <h3> 7.1.3. Related quantifications upon various treatments</h3> <h2> 7.2. Immunofluorescence images</h2> <h2> 7.3. T cell proliferation</h2> <h2> 7.4. DC proliferation</h2> <h1>8. <em>In vivo</em> anti-tumor efficacy</h1> <h2> 8.0. Lab book pages</h2> <h2> 8.1. Tumor growth</h2> <h3> 8.1.1. Tumor volume</h3> <h3> 8.1.2. Tumor weight</h3> <h3> 8.1.3. Tumor images</h3> <h2> 8.2. Body weight</h2> <h2> 8.3. Lung tissues with metastatic nodules</h2> <h3> 8.3.1. Lung tissues images</h3> <h3> 8.3.2. Number of pulmonary metastatic nodules</h3> <h3> 8.3.3. H&E</h3> <h2> 8.4. H&E of tumor and main organs</h2> <h2> 8.5. Cytokine secretions</h2> <h2> 8.6. Kaplan−Meier survival curves</h2> <h1>9. <em>In vitro</em> NK cytotoxicity and activity</h1> <h2> 9.0. Lab book pages</h2> <h2> 9.1. NK cytotoxicity</h2> <h2> 9.2. NK activity</h2>
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 4
- Access
- 16
- Reuse readiness
- 0
- Engagement
- 0